HLA-DO as the Optimizer of Epitope Selection for MHC Class II Antigen Presentation

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Poluektov, Yuri O ^a   Kim, AeRyon ^a   Hartman, Isamu Z ^a,b   Sadegh Nasseri, Scheherazade ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA DM ANTIGEN; HLA DO ANTIGEN; HLA DR1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN BINDING; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; ANTIGEN STRUCTURE; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; MOLECULAR INTERACTION; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; CELL LINE; EPITOPES; HLA-D ANTIGENS; HLA-DR1 ANTIGEN; HUMANS; INSECTS; KINETICS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS;

EID: 84881319397     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071228     Document Type: Article

References (70)

1. Neefjes JJ, Stollorz V, Peters PJ, Geuze HJ, Ploegh HL, (1990) The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell 61: 171-183.
2. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ, (1991) Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 349: 669-676.
3. Blum JS, Cresswell P, (1988) Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci U S A 85: 3975-3979.
4. Cresswell P, (1994) Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 12: 259-293.
5. Sadegh-Nasseri S, Germain RN, (1991) A role for peptide in determining MHC class II structure. Nature 353: 167-170.
6. Sadegh-Nasseri S, Germain RN, (1992) How MHC class II molecules work: peptide-dependent completion of protein folding. Immunol Today 13: 43-46.
7. Sadegh-Nasseri S, McConnell HM, (1989) A kinetic intermediate in the reaction of an antigenic peptide and I-Ek. Nature 337: 274-276.
8. Sadegh-Nasseri S, Stern LJ, Wiley DC, Germain RN, (1994) MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature 370: 647-650.
9. Sadegh-Nasseri S (1994) Peptide, invariant chain, or molecular aggregation preserves class II from functional inactivation In: Humphreys RE, Pierce SK, editors. Antigen processing and presentation. San Diego: Academic Press. 170-187.
10. Castellino F, Zhong G, Germain RN, (1997) Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture. Hum Immunol 54: 159-169.
11. Romagnoli P, Germain RN, (1994) The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med 180: 1107-1113.
12. Natarajan SK, Assadi M, Sadegh-Nasseri S, (1999) Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J Immunol 162: 4030-4036.
13. Sato AK, Zarutskie JA, Rushe MM, Lomakin A, Natarajan SK, et al. (2000) Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem 275: 2165-2173.
14. Mellins E, Smith L, Arp B, Cotner T, Celis E, et al. (1990) Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 343: 71-74.
15. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P, (1994) Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1: 595-606.
16. Fung-Leung WP, Surh CD, Liljedahl M, Pang J, Leturcq D, et al. (1996) Antigen presentation and T cell development in H2-M-deficient mice. Science 271: 1278-1281.
17. Denzin LK, Cresswell P, (1995) HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82: 155-165.
18. Green JM, DeMars R, Xu X, Pierce SK, (1995) The intracellular transport of MHC class II molecules in the absence of HLA-DM. J Immunol 155: 3759-3768.
19. Kropshofer H, Arndt SO, Moldenhauer G, Hammerling GJ, Vogt AB, (1997) HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6: 293-302.
20. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, et al. (1996) Editing of the HLA-DR-peptide repertoire by HLA-DM. Embo J 15: 6144-6154.
21. Miyazaki T, Wolf P, Tourne S, Waltzinger C, Dierich A, et al. (1996) Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 84: 531-541.
22. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, et al. (1996) H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 84: 543-550.
23. Weber DA, Evavold BD, Jensen PE, (1996) Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274: 618-620.
24. Ullrich HJ, Doring K, Gruneberg U, Jahnig F, Trowsdale J, et al. (1997) Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH. Proc Natl Acad Sci U S A 94: 13163-13168.
25. vogt AB, Moldenhauer G, Hammerling GJ, Kropshofer H, (1997) HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion. Immunol Lett 57: 209-211.
26. Chou CL, Sadegh-Nasseri S, (2000) HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med 192: 1697-1706.
27. Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED, (2000) Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 13: 517-527.
28. Narayan K, Chou CL, Kim A, Hartman IZ, Dalai S, et al. (2007) HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes. Nat Immunol 8: 92-100.
29. Pos W, Sethi DK, Call MJ, Schulze MS, Anders AK, et al. (2012) Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell 151: 1557-1568.
30. Anders AK, Call MJ, Schulze MS, Fowler KD, Schubert DA, et al. (2011) HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat Immunol 12: 54-61.
31. Belov K, Deakin JE, Papenfuss AT, Baker ML, Melman SD, et al. (2006) Reconstructing an ancestral mammalian immune supercomplex from a marsupial major histocompatibility complex. PLoS biology 4: e46.
32. Hornell TM, Burster T, Jahnsen FL, Pashine A, Ochoa MT, et al. (2006) Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J Immunol 176: 3536-3547.
33. Chen X, Reed-Loisel LM, Karlsson L, Jensen PE, (2006) H2-O expression in primary dendritic cells. Journal of immunology 176: 3548-3556.
34. Fallas JL, Yi W, Draghi NA, O'Rourke HM, Denzin LK, (2007) Expression patterns of H2-O in mouse B cells and dendritic cells correlate with cell function. J Immunol 178: 1488-1497.
35. Liljedahl M, Winqvist O, Surh CD, Wong P, Ngo K, et al. (1998) Altered antigen presentation in mice lacking H2-O. Immunity 8: 233-243.
36. Perraudeau M, Taylor PR, Stauss HJ, Lindstedt R, Bygrave AE, et al. (2000) Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice. Eur J Immunol 30: 2871-2880.
37. van Ham M, van Lith M, Lillemeier B, Tjin E, Gruneberg U, et al. (2000) Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J Exp Med 191: 1127-1136.
38. Yi W, Seth NP, Martillotti T, Wucherpfennig KW, Sant'Angelo DB, et al. (2010) Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. J Clin Invest 120: 1324-1336.
39. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P, (1997) Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 278: 106-109.
40. Jensen PE, (1998) Antigen processing: HLA-DO-a hitchhiking inhibitor of HLA-DM. Curr Biol 8: R128-131.
41. Kropshofer H, Vogt AB, Thery C, Armandola EA, Li BC, et al. (1998) A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. Embo J 17: 2971-2981.
42. Brocke P, Armandola E, Garbi N, Hammerling GJ, (2003) Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes. European journal of immunology 33: 411-421.
43. Natarajan SK, Stern LJ, Sadegh-Nasseri S, (1999) Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. J Immunol 162: 3463-3470.
44. Hartman IZ, Kim A, Cotter RJ, Walter K, Dalai SK, et al. (2010) A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes. Nat Med 16: 1333-1340.
45. Narayan K, Su KW, Chou CL, Khoruzhenko S, Sadegh-Nasseri S, (2009) HLA-DM mediates peptide exchange by interacting transiently and repeatedly with HLA-DR1. Mol Immunol 46: 3157-3162.
46. Kim A, Ishizuka I, Hartman IZ, Poluektov Y, Narayan K, et al. (2013) Studying MHC Class II Peptide Loading and Editing In Vitro. In: Peter M. van Endert P, editor. Antigen Processing: Methods and Protocols: Springer, Humana Press. 447-460.
47. Painter CA, Negroni MP, Kellersberger KA, Zavala-Ruiz Z, Evans JE, et al. (2011) Conformational lability in the class II MHC 310 helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchange. Proceedings of the National Academy of Sciences of the United States of America 108: 19329-19334.
48. Liljedahl M, Kuwana T, Fung-Leung WP, Jackson MR, Peterson PA, et al. (1996) HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. Embo J 15: 4817-4824.
49. Deshaies F, Brunet A, Diallo DA, Denzin LK, Samaan A, et al. (2005) A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM. Proc Natl Acad Sci U S A 102: 6443-6448.
50. Deshaies F, Diallo DA, Fortin JS, O'Rourke HM, Pezeshki AM, et al. (2009) Evidence for a human leucocyte antigen-DM-induced structural change in human leucocyte antigen-DObeta. Immunology 127: 408-417.
51. Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, et al. (1997) An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med 185: 1113-1122.
52. Fallas JL, Tobin HM, Lou O, Guo D, Sant'Angelo DB, et al. (2004) Ectopic expression of HLA-DO in mouse dendritic cells diminishes MHC class II antigen presentation. J Immunol 173: 1549-1560.
53. van Ham M, van Lith M, Griekspoor A, Neefjes J, (2000) What to do with HLA-DO? Immunogenetics 51: 765-770.
54. Rabinowitz JD, Vrljic M, Kasson PM, Liang MN, Busch R, et al. (1998) Formation of a highly peptide-receptive state of class II MHC. Immunity 9: 699-709.
55. Guce AI, Mortimer SE, Yoon T, Painter CA, Jiang W, et al. (2012) HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nature structural & molecular biology.
56. Grover HS, Blanchard N, Gonzalez F, Chan S, Robey EA, et al. (2012) The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden. Infection and immunity 80: 3279-3288.
57. Yoon T, Macmillan H, Mortimer SE, Jiang W, Rinderknecht CH, et al. (2012) Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis. Proceedings of the National Academy of Sciences of the United States of America 109: 11276-11281.
58. Kremer AN, van der Meijden ED, Honders MW, Goeman JJ, Wiertz EJ, et al. (2012) Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO. Blood 120: 3246-3255.
59. Schulze MS, Wucherpfennig KW, (2012) The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway. Current opinion in immunology 24: 105-111.
60. Pu Z, Lovitch SB, Bikoff EK, Unanue ER, (2004) T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 20: 467-476.
61. Stratikos E, Wiley DC, Stern LJ, (2004) Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain. J Immunol 172: 1109-1117.
62. Soll SJ, Stewart BS, Lehman N, (2005) Conservation of MHC class II DOA sequences among carnivores. Tissue Antigens 65: 283-286.
63. Draghi NA, Denzin LK, (2010) H2-O, a MHC class II-like protein, sets a threshold for B-cell entry into germinal centers. Proc Natl Acad Sci U S A 107: 16607-16612.
64. Alfonso C, Williams GS, Han JO, Westberg JA, Winqvist O, et al. (2003) Analysis of H2-O influence on antigen presentation by B cells. J Immunol 171: 2331-2337.
65. Vezys V, Yates A, Casey KA, Lanier G, Ahmed R, et al. (2009) Memory CD8 T-cell compartment grows in size with immunological experience. Nature 457: 196-199.
66. Whitmire JK, Asano MS, Kaech SM, Sarkar S, Hannum LG, et al. (2009) Requirement of B cells for generating CD4+ T cell memory. J Immunol 182: 1868-1876.
67. Dalai SK, Mirshahidi S, Morrot A, Zavala F, Sadegh-Nasseri S, (2008) Anergy in memory CD4+ T cells is induced by B cells. J Immunol 181: 3221-3231.
68. Dalai SK, Khoruzhenko S, Drake CG, Jie CC, Sadegh-Nasseri S (2011) Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells. Immunol Cell Biol.
69. Dzhagalov IL, Chen KG, Herzmark P, Robey EA, (2013) Elimination of self-reactive T cells in the thymus: a timeline for negative selection. PLoS biology 11: e1001566.
70. Reynolds RJ, Kelley JM, Hughes LB, Yi N, Bridges SL Jr, (2010) Genetic association of htSNPs across the major histocompatibility complex with rheumatoid arthritis in an African-American population. Genes and immunity 11: 94-97.